SEZ6L2

Across TCGA pan-cancer cohorts, SEZ6L2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SEZ6L2 data layer compared with 20 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher SEZ6L2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SEZ6L2 expression acts as an unfavorable survival marker.

SCLC, HNSC, and OV are the cancer types where SEZ6L2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	All	0.082	0.708	<.001	36	view →
HNSC	OS	Median	All	0.210	0.686	.012	18	view →
OV	DFS	Median	II,III,IV	0.268	0.541	.027	12	view →
COAD	OS	Median	IV	0.082	0.659	<.001	12	view →
LIHC	DFS	Median	II,III,IV	0.076	0.431	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	OS	Median	III,IV	0.530	0.852	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SEZ6L2–SCLC (OS)

Open the SCLC breakdown →